342 related articles for article (PubMed ID: 10796790)
41. [A comparative analysis of the effectiveness of serenoa repens and serenoa repens in combination with urtica dioiccus for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue].
Ibishev KS; Krainy PA; Mitusov VV; Sizyakin DV; Magomedov GA
Urologiia; 2019 Apr; (1):40-46. PubMed ID: 31184016
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
Zlotta AR; Teillac P; Raynaud JP; Schulman CC
Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527
[TBL] [Abstract][Full Text] [Related]
43. The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Gerber GS; Fitzpatrick JM
BJU Int; 2004 Aug; 94(3):338-44. PubMed ID: 15291864
[TBL] [Abstract][Full Text] [Related]
44. Effects of Serenoa repens Alcohol Extract on Benign Prostate Hyperplasia.
Saidi S; Stavridis S; Stankov O; Dohcev S; Panov S
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Sep; 38(2):123-129. PubMed ID: 28991765
[TBL] [Abstract][Full Text] [Related]
45. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
Carraro JC; Raynaud JP; Koch G; Chisholm GD; Di Silverio F; Teillac P; Da Silva FC; Cauquil J; Chopin DK; Hamdy FC; Hanus M; Hauri D; Kalinteris A; Marencak J; Perier A; Perrin P
Prostate; 1996 Oct; 29(4):231-40; discussion 241-2. PubMed ID: 8876706
[TBL] [Abstract][Full Text] [Related]
46. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia.
Boyle P; Robertson C; Lowe F; Roehrborn C
Urology; 2000 Apr; 55(4):533-9. PubMed ID: 10736497
[TBL] [Abstract][Full Text] [Related]
47. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
[TBL] [Abstract][Full Text] [Related]
48. [Prediction of the effectiveness of the therapy of LUTS/BPH by Serenoa repens extracts].
Sivkov AV; Golovanov SA; Zhukova LV
Urologiia; 2019 Jul; (3):14-22. PubMed ID: 31356008
[TBL] [Abstract][Full Text] [Related]
49. Role of phytotherapy in men with lower urinary tract symptoms.
Fong YK; Milani S; Djavan B
Curr Opin Urol; 2005 Jan; 15(1):45-8. PubMed ID: 15586030
[TBL] [Abstract][Full Text] [Related]
50. A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia.
Hizli F; Uygur MC
Int Urol Nephrol; 2007; 39(3):879-86. PubMed ID: 17203353
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens.
Stepanov VN; Siniakova LA; Sarrazin B; Raynaud JP
Adv Ther; 1999; 16(5):231-41. PubMed ID: 10915398
[TBL] [Abstract][Full Text] [Related]
52. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials.
Kahokehr A; Vather R; Nixon A; Hill AG
BJU Int; 2013 Feb; 111(2):304-11. PubMed ID: 23356748
[TBL] [Abstract][Full Text] [Related]
53. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.
Sökeland J
BJU Int; 2000 Sep; 86(4):439-42. PubMed ID: 10971268
[TBL] [Abstract][Full Text] [Related]
54. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia.
Vela-Navarrete R; Escribano-Burgos M; Farré AL; García-Cardoso J; Manzarbeitia F; Carrasco C
J Urol; 2005 Feb; 173(2):507-10. PubMed ID: 15643230
[TBL] [Abstract][Full Text] [Related]
55. Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies.
Mantovani F
Minerva Urol Nefrol; 2010 Dec; 62(4):335-40. PubMed ID: 20944533
[TBL] [Abstract][Full Text] [Related]
56. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia.
Pytel YA; Vinarov A; Lopatkin N; Sivkov A; Gorilovsky L; Raynaud JP
Adv Ther; 2002; 19(6):297-306. PubMed ID: 12665050
[TBL] [Abstract][Full Text] [Related]
57. [Five-year experience in treating patients with prostatic hyperplasia patients with permixone (Serenoa repens "Pierre Fabre Medicament)].
Aliaev IuG; Vinarov AZ; Lokshin KL; Spivak LG
Urologiia; 2002; (1):23-5. PubMed ID: 11877967
[TBL] [Abstract][Full Text] [Related]
58. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
Di Silverio F; Monti S; Sciarra A; Varasano PA; Martini C; Lanzara S; D'Eramo G; Di Nicola S; Toscano V
Prostate; 1998 Oct; 37(2):77-83. PubMed ID: 9759701
[TBL] [Abstract][Full Text] [Related]
59. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP
Eur Urol; 2002 May; 41(5):497-506; discussion 506-7. PubMed ID: 12074791
[TBL] [Abstract][Full Text] [Related]
60. [Is there a rational therapy for symptomatic treatment of benign prostatic hyperplasia with phytogenic drugs? Illustrated with the example of the prostate agent from Serenoa repens (Sabal fructus)].
Schilcher H
Wien Med Wochenschr; 1999; 149(8-10):236-40. PubMed ID: 10483690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
